“This was a useful overview of vascular, pigmentary, and ablative lasers. The main recent shift is away from choosing a laser only by its wavelength, toward individualized, combination treatment based on the dominant chromophore, lesion depth, skin phototype, and downtime acceptable to the patient.

For vascular lesions, pulsed-dye laser remains the workhorse for superficial erythema and telangiectasia, while long-pulsed 1064-nm Nd:YAG is useful for deeper or larger-calibre vessels. IPL and narrow-band IPL are increasingly used for diffuse erythema and rosacea, but parameter selection and cooling remain essential.

In pigmentary disorders, picosecond lasers with fractional diffractive lens arrays are an important development because they deliver more photoacoustic pigment fragmentation with less bulk thermal injury. However, in melasma and darker skin types, laser should be viewed as an adjunct, not a standalone cure, because post-inflammatory hyperpigmentation and recurrence are still important concerns. A 2023 systematic review found benefit with picosecond lasers for melasma but also supports cautious patient selection and combination maintenance therapy Feng et al..

In ablative resurfacing, fractional CO2 and fractional Er:YAG have made treatment safer than fully ablative resurfacing. The newer practice is not necessarily a new machine, but more precise fractional density, energy, and pulse customization, plus combining vascular laser for erythema, pigment laser for dyschromia, and fractional ablative laser for texture or scars. This multimodal approach is particularly relevant for mixed scars.”

1. Fractional picosecond technology: useful for pigment, dyschromia, tattoos, and selected textural indications, with reduced thermal diffusion compared with traditional nanosecond Q-switched devices.
2. Combination and sequential protocols: for example, PDL or Nd:YAG for scar erythema followed by fractional CO2/Er:YAG for texture and remodeling. Recent reviews describe this as a rational approach for scars with vascular, pigmentary, and textural components.
3. Safer treatment in skin of colour: lower density, conservative fluence, longer intervals, strict photoprotection, pigment-suppressing topical therapy where appropriate, and careful counselling about PIH.
4. Fractional ablative laser-assisted drug delivery: creating microchannels with fractional CO2 or Er:YAG to enhance delivery of selected topical agents. This is promising but requires careful indication-specific protocols.
5. Objective treatment planning: dermoscopy, standardized photography, colour analysis, and sometimes imaging-based assessment help distinguish vascular redness from pigment and prevent inappropriate laser selection.
6. More realistic outcomes: the current standard is to discuss recurrence, maintenance, and combination medical therapy, especially in melasma and rosacea, rather than promising permanent clearance.

“An important take-home point is that newer laser platforms do not replace clinical diagnosis and chromophore-based treatment selection. The best outcomes still depend on matching wavelength, pulse duration, spot size, fluence, cooling, and treatment density to lesion depth and patient skin type.”